ArticleCancer research2019
MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 36 citations in OpenAlex.
- RAB1A is a novel vulnerability in uveal melanoma revealed by dual inhibition of MNK1/2 and mTOR.Cell death and differentiation · 2026Article
- Aptamer-based inhibition of MNK1 reduces pancreatic ductal adenocarcinoma growth by targeting cancer stem cells.Journal of biomedical science · 2026Article
- Article
- Enhancing oncolytic virotherapy with a tri-specific T-cell engager targeting CD3ε, EpCaM, and 4-1BB: preclinical evaluation and implications for cancer immunotherapy.BMC medicine · 2026Article
- Blocking tumor-intrinsic MNK1 kinase restricts metabolic adaptation and diminishes liver metastasis.Science advances · 2024Article
- The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment.Nature reviews. Cancer · 2023Review
- An Aptamer against MNK1 for Non-Small Cell Lung Cancer Treatment.Pharmaceutics · 2023Article
- Identification ofComputational and structural biotechnology journal · 2023Article
- Article
- Insights into the transition of ductal carcinomaCancer biology & medicine · 2022Article
- Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients.Journal of the Egyptian National Cancer Institute · 2022Article
- Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study.Cell death & disease · 2022Article
- A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens.International journal of molecular sciences · 2022Article
- Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.Molecular cancer therapeutics · 2022Article
- Global signalling network analysis of luminal T47D breast cancer cells in response to progesterone.Frontiers in endocrinology · 2022Article
- Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.The Journal of clinical investigation · 2021Article
- Embryonic protein NODAL regulates the breast tumor microenvironment by reprogramming cancer-derived secretomes.Neoplasia (New York, N.Y.) · 2021Article
- MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma.Oncogene · 2021Article
- Cancer Plasticity: The Role of mRNA Translation.Trends in cancer · 2021Review
- Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy.Frontiers in oncology · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
29 authors at 7 institutions in 3 countries.
Qianyu GuoDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada.
Vivian Z LiDepartment of Oncology, Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.ORCID 0000-0001-6983-3762
Jessica N NicholDepartment of Oncology, Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.
Fan HuangDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada.ORCID 0000-0002-3850-5317
William YangDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada.
Samuel E J PrestonDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada.
Zahra TalatDepartment of Oncology, Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.ORCID 0000-0001-8988-5471
Hanne LefrèreDepartment of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium.
Henry YuDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada.
Guihua ZhangCancer Research Institute of Northern Alberta, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Mark BasikDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada.
Christophe GonçalvesDepartment of Oncology, Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.
Yao ZhanDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada.
Dany PlourdeDepartment of Oncology, Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.
Jie SuDepartment of Oncology, Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.
Jose TorresDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada.ORCID 0000-0002-9957-6004
Maud MarquesDepartment of Oncology, Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.
Sara Al HabyanGoodman Cancer Centre, McGill University, Montréal, Québec, Canada.
Krikor BijianDepartment of Oncology, Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.
Frédéric AmantDepartment of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium.
Michael WitcherDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada.
Fariba BehbodDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Centre, Kansas City, Kansas.
Luke McCaffreyDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada.
Moulay Alaoui-JamaliDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada.ORCID 0000-0002-7824-4190
Nadia V GiannakopoulosDepartment of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0001-7543-088X
Muriel BrackstoneDepartments of Surgery and Oncology, Western University, London, Ontario, Canada.
Lynne-Marie PostovitCancer Research Institute of Northern Alberta, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
Sonia V Del RincónDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada. wmiller@ldi.jgh.mcgill.ca sonia.delrincon@mcgill.ca.
Wilson H MillerDivision of Experimental Medicine, McGill University, Montréal, Québec, Canada. wmiller@ldi.jgh.mcgill.ca sonia.delrincon@mcgill.ca.
Jewish General Hospital · CAKU Leuven · BEMcGill University Health Centre · CAUniversity of Alberta · CANorthern Alberta Institute of Technology · CAUniversity of Kansas Medical Center · USWestern University · CA
Funding
Identifying the Molecular and Cellular Basis of Invasive Phenotype in Human DCISR01CA207445 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BEHBOD, FARIBA · 2017 to 2019
$1.7MA novel N-Ras pathway driving DCIS to basal-like breast cancerR21CA226567 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CHANG, ERIC C · 2018 to 2019
$377kCIHR MOP-142281CIHR PJT-156269NCI NIH HHS R01 CA207445NCI NIH HHS R21 CA226567
Abstract
The mechanisms by which breast cancers progress from relatively indolent ductal carcinoma
Indexed as
Signal TransductionAnimalsBreast Carcinoma In SituBreast NeoplasmsCarcinoma, Ductal, BreastCell Line, TumorCell ProliferationCRISPR-Cas SystemsDisease ProgressionFemaleHeterograftsHumansIntracellular Signaling Peptides and ProteinsMiceMice, NudeNodal ProteinIntracellular Signaling Peptides and ProteinsMKNK1 protein, humanNodal ProteinNODAL protein, humanProtein Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.